Definition of risk groups according to the EORTC/LYSA and the GHSG
| Risk group . | EORTC/LYSA . | GHSG . |
|---|---|---|
| Early stages | CS I-II without risk factors (supradiaphragmatic) | CS I-II without risk factors |
| Intermediate stages | CS I-II with ≥1 risk factors (supradiaphragmatic) | CS I, CS IIA with ≥1 risk factors |
| CS IIB with risk factors C/D, but not A/B | ||
| Advanced stages | CS III-IV | CS IIB with risk factors A/B, CS III/IV |
| Risk factors | (A) large mediastinal mass | (A) large mediastinal mass |
| (B) age ≥50 y | (B) extranodal disease | |
| (C) elevated ESR | (C) elevated ESR | |
| (D) ≥4 nodal areas | (D) ≥3 nodal areas |
| Risk group . | EORTC/LYSA . | GHSG . |
|---|---|---|
| Early stages | CS I-II without risk factors (supradiaphragmatic) | CS I-II without risk factors |
| Intermediate stages | CS I-II with ≥1 risk factors (supradiaphragmatic) | CS I, CS IIA with ≥1 risk factors |
| CS IIB with risk factors C/D, but not A/B | ||
| Advanced stages | CS III-IV | CS IIB with risk factors A/B, CS III/IV |
| Risk factors | (A) large mediastinal mass | (A) large mediastinal mass |
| (B) age ≥50 y | (B) extranodal disease | |
| (C) elevated ESR | (C) elevated ESR | |
| (D) ≥4 nodal areas | (D) ≥3 nodal areas |
Elevated ESR is defined as >50 mm/h without B symptoms and >30 mm/h with B symptoms. Large mediastinal mass is defined as more than one third of the maximum horizontal chest diameter. B symptoms are fever, night sweats, and unexplained weight loss of >10% over 6 mo. CS, clinical stage; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; LYSA, Lymphoma Study Association.